Biogen Inc. $BIIB Stock Acquired by Barrett & Company Inc.

Barrett & Company Inc. lifted its position in shares of Biogen Inc. (NASDAQ:BIIB) by 8,483.3% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,575 shares of the biotechnology company’s stock after acquiring an additional 2,545 shares during the quarter. Barrett & Company Inc.’s holdings in Biogen were worth $582,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also made changes to their positions in the company. Bell Investment Advisors Inc purchased a new stake in shares of Biogen during the second quarter worth $27,000. Align Financial LLC grew its position in shares of Biogen by 339.3% in the third quarter. Align Financial LLC now owns 123 shares of the biotechnology company’s stock valued at $28,000 after purchasing an additional 95 shares in the last quarter. Ashurst Perkins Coie Trust Co increased its holdings in shares of Biogen by 92.2% in the third quarter. Ashurst Perkins Coie Trust Co now owns 173 shares of the biotechnology company’s stock valued at $39,000 after purchasing an additional 83 shares during the last quarter. Cassaday & Co Wealth Management LLC acquired a new stake in shares of Biogen in the first quarter valued at approximately $40,000. Finally, Albion Financial Group UT lifted its position in Biogen by 2,833.3% during the third quarter. Albion Financial Group UT now owns 176 shares of the biotechnology company’s stock worth $40,000 after buying an additional 170 shares in the last quarter. 87.93% of the stock is currently owned by hedge funds and other institutional investors.

Biogen Price Performance

Shares of NASDAQ:BIIB opened at $250.69 on Friday. Biogen Inc. has a one year low of $138.00 and a one year high of $254.41. The business’s fifty day moving average price is $223.60 and its two-hundred day moving average price is $206.04. The company has a debt-to-equity ratio of 0.39, a quick ratio of 1.26 and a current ratio of 1.87. The stock has a market cap of $37.04 billion, a PE ratio of 44.37, a price-to-earnings-growth ratio of 2.83 and a beta of 0.09.

Biogen (NASDAQ:BIIB) last posted its earnings results on Wednesday, July 29th. The biotechnology company reported $3.60 EPS for the quarter, topping analysts’ consensus estimates of $2.94 by $0.66. Biogen had a net margin of 8.32% and a return on equity of 11.18%. The business had revenue of $2.74 billion for the quarter, compared to analysts’ expectations of $2.46 billion. During the same period in the previous year, the company posted $5.47 earnings per share. The business’s revenue for the quarter was up 3.4% compared to the same quarter last year. Biogen has set its FY 2026 guidance at 12.000-13.000 EPS. On average, analysts forecast that Biogen Inc. will post 12.29 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms have commented on BIIB. Royal Bank Of Canada reduced their target price on Biogen from $260.00 to $256.00 and set an “outperform” rating on the stock in a research report on Thursday, October 8th. Stifel Nicolaus set a $242.00 price objective on shares of Biogen in a research report on Thursday, September 10th. Wolfe Research raised Biogen from a “peer perform” rating to an “outperform” rating and set a $300.00 target price on the stock in a research note on Thursday, August 13th. Piper Sandler reissued an “overweight” rating and issued a $245.00 price objective (up from $225.00) on shares of Biogen in a research note on Thursday, September 3rd. Finally, JPMorgan Chase & Co. raised shares of Biogen from a “neutral” rating to an “overweight” rating and raised their price target for the company from $210.00 to $300.00 in a research report on Monday, October 12th. One research analyst has rated the stock with a Strong Buy rating, nineteen have given a Buy rating, eleven have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $241.89.

Biogen Profile

Biogen Inc is a biotechnology company that discovers, develops and commercializes therapies for neurological and neurodegenerative diseases. Its areas of focus include multiple sclerosis, Alzheimer’s disease, spinal muscular atrophy, amyotrophic lateral sclerosis and other serious medical conditions.

The company’s portfolio includes multiple sclerosis treatments such as Tecfidera, Vumerity, Tysabri, Plegridy and Avonex, as well as Spinraza for spinal muscular atrophy. Biogen also markets Leqembi, an Alzheimer’s disease treatment developed in collaboration with Eisai, and works with partners to advance additional therapies and biosimilars.

Biogen was founded in 1978 and is headquartered in Cambridge, Massachusetts.